MVMDF Quote, Financials, Valuation and Earnings

Edesa Biotech, Inc. has a net margin of -2367.55% compared to Mountain Valley MD Holdings, Inc.'s net margin of --. Mountain Valley MD Holdings, Inc.'s return on equity of -165.2% beat Edesa Biotech, Inc.'s return on equity of -80.46%.

Mountain Valley MD Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $10.33 which suggests that it could grow by 514.53%. Given that Edesa Biotech, Inc. has higher upside potential than Mountain Valley MD Holdings, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Mountain Valley MD Holdings, Inc..

Mountain Valley MD Holdings, Inc. has a beta of 0.986, which suggesting that the stock is 1.422% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Mountain Valley MD Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mountain Valley MD Holdings, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Mountain Valley MD Holdings, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Mountain Valley MD Holdings, Inc.'s net income of -$440K is higher than Edesa Biotech, Inc.'s net income of -$1.7M. Notably, Mountain Valley MD Holdings, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mountain Valley MD Holdings, Inc. is 145.58x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of -2367.55% compared to Mountain Valley MD Holdings, Inc.'s net margin of -2178.51%. Mountain Valley MD Holdings, Inc.'s return on equity of -165.2% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

Mountain Valley MD Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 371.98%. Given that Lexaria Bioscience Corp. has higher upside potential than Mountain Valley MD Holdings, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Mountain Valley MD Holdings, Inc..

Mountain Valley MD Holdings, Inc. has a beta of 0.986, which suggesting that the stock is 1.422% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

Mountain Valley MD Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mountain Valley MD Holdings, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Mountain Valley MD Holdings, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of $174K. Mountain Valley MD Holdings, Inc.'s net income of -$440K is higher than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Mountain Valley MD Holdings, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mountain Valley MD Holdings, Inc. is 145.58x versus 28.83x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -2367.55% compared to Mountain Valley MD Holdings, Inc.'s net margin of --. Mountain Valley MD Holdings, Inc.'s return on equity of -165.2% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Mountain Valley MD Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 461.59%. Given that Oncolytics Biotech, Inc. has higher upside potential than Mountain Valley MD Holdings, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Mountain Valley MD Holdings, Inc..

Mountain Valley MD Holdings, Inc. has a beta of 0.986, which suggesting that the stock is 1.422% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Mountain Valley MD Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mountain Valley MD Holdings, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Mountain Valley MD Holdings, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Mountain Valley MD Holdings, Inc.'s net income of -$440K is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Mountain Valley MD Holdings, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mountain Valley MD Holdings, Inc. is 145.58x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of -2367.55% compared to Mountain Valley MD Holdings, Inc.'s net margin of -867.29%. Mountain Valley MD Holdings, Inc.'s return on equity of -165.2% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.

Mountain Valley MD Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.19 which suggests that it could grow by 26.82%. Given that Xenon Pharmaceuticals, Inc. has higher upside potential than Mountain Valley MD Holdings, Inc., analysts believe Xenon Pharmaceuticals, Inc. is more attractive than Mountain Valley MD Holdings, Inc..

Mountain Valley MD Holdings, Inc. has a beta of 0.986, which suggesting that the stock is 1.422% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.

Mountain Valley MD Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mountain Valley MD Holdings, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Mountain Valley MD Holdings, Inc. quarterly revenues are --, which are smaller than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Mountain Valley MD Holdings, Inc.'s net income of -$440K is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Mountain Valley MD Holdings, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mountain Valley MD Holdings, Inc. is 145.58x versus 457.36x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.